A world leader in the development of dendrimer products for pharmaceutical, life science, Starpharma Holdings Limited (ASX:SPL) revealed the completion of the phase 1 component of its phase 1/2 clinical trial for DEP® irinotecan.
The phase 1 clinical trial met its aim of evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy data including recommended dose for phase 2 trial.
Moreover, the company mentioned the commencement of phase 2 trial, which is for establishing anti-tumour activity and safety of DEP® irinotecan.
Share price of SPL stock climbed by 3.125% to $0.990, on 7 May 2020.
Disclaimer
There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.
Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.
As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.
